SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

CCCX is trending as Infleqtion, its quantum technology merger target, garners significant attention for its role in a NASA space mission and a U.S. Department of Energy contract, leading to community discussion around its perceived undervaluation against quantum peers and high expectations for its upcoming merger and NYSE debut as INFQ.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is navigating intense investor speculation ahead of its earnings report, fueling a stark divide between bulls anticipating a significant short squeeze driven by its AI lending model and critics lamenting consistent underperformance and management's perceived lack of communication. The broader fintech sector's volatility and concerns over consumer credit health continue to weigh heavily on community sentiment, making the stock a focal point for both potential rebound and further weakness.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is rallying following its European CE Mark approval for the Eversense 365 CGM and the first commercial integration with the twiist automated insulin delivery system, with the community highly anticipating broader adoption of its superior one-year implantable technology despite historical management concerns and ongoing market volatility.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as widespread user frustration mounts over persistent platform outages and trading restrictions, especially with its ThinkorSwim platform. Despite recent positive financial updates and a substantial share buyback program, the community is actively discussing these reliability issues and the possibility of switching to alternative brokers.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending due to a strong Q4 earnings beat and optimistic outlook, with the community highlighting reaccelerated revenue growth and surging RPO driven by both core and AI-native customers. This robust performance is viewed as a significant positive signal for the broader software sector, suggesting a potential end to its recent slowdown.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending after bearish 2026 guidance, driven by DefenCath's post-TDAPA reimbursement concerns, caused a significant stock decline. The community is highly critical of management's communication, while simultaneously anticipating updates from an upcoming Analyst Day, a $75 million share repurchase program, and potential legislative support to counter heavy short interest and prove the stock's perceived undervaluation.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending amidst a sharp stock decline following its Q4 earnings report, which revealed strong revenue growth and a substantial reduction in cash burn. This has sparked significant community discussion around whether the market is overlooking the company's fundamental improvements and clearer path to profitability.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending following strong long-term maintenance data for its atopic dermatitis drug, rezpegaldesleukin, which showcased durable efficacy and a favorable safety profile. This has fueled widespread community discussion about the drug's significant market potential and multiple analyst firms revising their outlooks upwards.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending following a significant earnings beat and strong outlook, with record user growth, expanding margins, and robust Q1 guidance signaling confidence in its path to sustained profitability. The community is actively debating whether these results, coupled with new AI features and content initiatives, cement its transition from a pure growth story to a high-margin cash generator amidst concerns about valuation and market competition.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is trending sharply higher following positive top-line data from its Phase 2a trial for EVO301, an eczema drug, prompting widespread community discussion around significant upside potential and a short squeeze play, though some traders remain skeptical of its fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026

LLY posts 45% revenue growth to $65.2B in 2025 as GLP-1 drugs power results, and guides $80-$83B in sales with EPS up over 40% in 2026.

Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Principal Financial Group Inc. lowered its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 7.7% in the 3rd quarter, according to its most recent Form...

Structure Therapeutics (NASDAQ:GPCR) Shares Down 10.7% - Here's Why

Structure Therapeutics (NASDAQ:GPCR) Trading Down 10.7% - Here's Why...

Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook

Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.

Structure Therapeutics (NASDAQ:GPCR) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Structure Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

CCG Wealth Management LLC Sells 140,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

CCG Wealth Management LLC cut its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 93.3% during the 3rd quarter, according to its most recent Form 13F filing with the...

Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape obesity treatment.read more...

Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

JPMorgan Chase & Co. increased their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday...

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space...

Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

Pacific Heights Asset Management LLC increased its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 52.2% in the third quarter, according to its most recent...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR